Samsung Biologics Co., Ltd.
Samsung Biologics Co., Ltd. is a biopharmaceutical contract development and manufacturing organization (CDMO) headquartered at 300 Songdo bio-daero, Yeonsu-gu, Incheon 21987, South Korea, founded in 2011 and listed on the Korea Exchange under ticker 207940. For fiscal 2025 Samsung Biologics reported revenue of US$3.25 billion and net income of US$1.11 billion — a net margin near 34%, against US$0.99 billion of revenue in 2020. Market capitalisation stood at US$49.12 billion as of 2026-10, with shares at KRW 1,466,000, and the workforce numbers about 5,000 employees. Brands include S-CHOice, S-Cellerate, S-Dual and Samsung Bioepis.
Strengths: Samsung Biologics has scaled revenue roughly threefold from US$0.99 billion in 2020 to US$3.25 billion in 2025 while lifting net income from US$0.2 billion to US$1.11 billion, showing operating leverage. Backing from Samsung C&T (~43.1%) and Samsung Electronics (~31.2%) gives parent-level balance-sheet support, and its branded platforms — S-CHOice, S-Cellerate and S-Dual — position it across formulation, accelerated development and bispecific formats. A 5,000-strong workforce concentrated at the Songdo site supports integrated development and manufacturing under one roof.
Weaknesses: Growth stalled in 2025, with revenue slipping from US$3.3 billion to US$3.25 billion and total assets falling from KRW 17,336.3 billion to KRW 11,060.74 billion. Manufacturing is concentrated at a single Incheon campus, so any site disruption or quality event would hit output directly. Ownership is tightly held by Samsung Group affiliates, and a market capitalisation of US$49.12 billion against US$3.25 billion of revenue leaves little room for error.
Read MoreShow Less
Samsung Biologics Co., Ltd. is a biopharmaceutical contract development and manufacturing organization (CDMO) headquartered at 300 Songdo bio-daero, Yeonsu-gu, Incheon 21987, South Korea, founded in 2011 and listed on the Korea Exchange under ticker 207940. For fiscal 2025 Samsung Biologics reported revenue of US$3.25 billion and net income of US$1.11 billion — a net margin near 34%, against US$0.99 billion of revenue in 2020. Market capitalisation stood at US$49.12 billion as of 2026-10, with shares at KRW 1,466,000, and the workforce numbers about 5,000 employees. Brands include S-CHOice, S-Cellerate, S-Dual and Samsung Bioepis.
Strengths: Samsung Biologics has scaled revenue roughly threefold from US$0.99 billion in 2020 to US$3.25 billion in 2025 while lifting net income from US$0.2 billion to US$1.11 billion, showing operating leverage. Backing from Samsung C&T (~43.1%) and Samsung Electronics (~31.2%) gives parent-level balance-sheet support, and its branded platforms — S-CHOice, S-Cellerate and S-Dual — position it across formulation, accelerated development and bispecific formats. A 5,000-strong workforce concentrated at the Songdo site supports integrated development and manufacturing under one roof.
Weaknesses: Growth stalled in 2025, with revenue slipping from US$3.3 billion to US$3.25 billion and total assets falling from KRW 17,336.3 billion to KRW 11,060.74 billion. Manufacturing is concentrated at a single Incheon campus, so any site disruption or quality event would hit output directly. Ownership is tightly held by Samsung Group affiliates, and a market capitalisation of US$49.12 billion against US$3.25 billion of revenue leaves little room for error.
Listed market data
207940 · KRX · weeklyHistory →- Market cap
- $49.1 B
- Share price
- —
- 1Y change
- —
- Recent change
- —
- Since first close
- —
- Revenue (TTM)
- US$3.3 B (FY2025)
• Samsung Biologics Co., Ltd. was founded in 2011.
• Headquarters are at 300 Songdo bio-daero, Yeonsu-gu, Incheon 21987, South Korea.
• It is listed on the KRX under ticker 207940.
Operations – CDMO and brands
• Industry focus: biopharmaceutical / biologics contract development and manufacturing CDMO.
• Brands include Samsung Biologics, S-CHOice, S-Cellerate, S-Dual and Samsung Bioepis.
• Headcount is 5,000 employees.
Ownership – group structure
• Affiliated with Samsung Group.
• Samsung C&T holds approximately 43.1%.
• Samsung Electronics holds approximately 31.2%.
Financials – recent scale
• 2025 revenue was US$3.25 billion.
• 2025 net income was US$1.11 billion.
• Market capitalization was US$49.12 billion as of 2026-10.
| Fiscal year | Revenue | Net income |
|---|---|---|
| 2025 | $3.3 B | $1.1 B |
| 2024 | $3.3 B | $790 M |
| 2023 | $2.8 B | $660 M |
| 2022 | $2.3 B | $620 M |
| 2021 | $1.4 B | $340 M |
| 2020 | $990 M | $200 M |
Annual results from company filings (SEC XBRL), converted to US dollars.
Quick Facts
Headquarters
Incheon, South Korea
Founded
2011
Employees
5,000
Revenue
US$3.3 B (FY2025)
Market cap
$49.1 B
Factories
Biologics manufacturing plants in Songdo, Incheon, South Korea
Presence
Global biopharma clients in US, EU, and Asia
Listing
listed
Data Sources & Methodology
This corporate profile is compiled from publicly available sources including company annual reports, SEC/regulatory filings, official press releases, and verified third-party industry databases. Financial figures reflect the most recent fiscal year disclosures and are cross-validated across multiple independent references.
VerityRank Score is calculated using a proprietary multi-dimensional model evaluating market presence, financial strength, operational scale, innovation capacity, and brand influence. Individual dimension scores are normalized against industry peers and updated quarterly.
Disclaimer: This profile is for informational purposes only. VerityRank makes no warranties regarding completeness or timeliness. This content does not constitute investment advice or endorsement.
Key references: Official Website